Iterum Therapeutics (NASDAQ:ITRM) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Iterum Therapeutics (NASDAQ:ITRM) in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a $6.00 price objective on the stock.

Iterum Therapeutics Stock Performance

Shares of ITRM stock opened at $1.24 on Friday. The firm has a market capitalization of $20.53 million, a PE ratio of -0.47 and a beta of 2.29. The company has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.57. Iterum Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.50. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 3.63.

Iterum Therapeutics (NASDAQ:ITRM) last posted its earnings results on Monday, May 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. As a group, equities research analysts expect that Iterum Therapeutics will post -1.76 earnings per share for the current year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.